Investigational drug · Phase 2
coformulation pembrolizumab
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Small Cell Lung Carcinoma.
Phase 2Last checked: Nov 20, 2026Latest source record: Jun 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
22
Any phase or sponsor naming "coformulation pembrolizumab"
First trial start
2021
Aug 19, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "coformulation pembrolizumab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Small Cell Lung Carcinoma
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "coformulation pembrolizumab" as an intervention, largest first.
- A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)Pivotal-lookingTerminated
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05665595 · 1,594 participants · Start Jan 19, 2023 · Primary completion Mar 6, 2024
Drug: Pembrolizumab/Vibostolimab; Pembrolizumab · For: Melanoma
Sites: La Jolla, California; Los Angeles, California; San Francisco, California · 205 sites in all
- Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)Pivotal-lookingTerminated
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04738487 · 1,264 participants · Start Apr 7, 2021 · Primary completion Sep 5, 2024
Drug: Pembrolizumab/Vibostolimab; Pembrolizumab · For: Lung Neoplasms; Non-Small-Cell Lung Carcinoma
Sites: Boca Raton, Florida; Peoria, Illinois; Springfield, Missouri · 188 sites in all
- Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)Active, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT02861573 · 1,200 participants (planned) · Start Nov 17, 2016 · Primary completion Oct 22, 2027
Drug: Pembrolizumab 200 mg; Olaparib 400 mg and 10 more · For: Metastatic Castration-Resistant Prostate Cancer
- Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)Pivotal-lookingTerminated
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05226598 · 739 participants · Start Mar 24, 2022 · Primary completion Sep 24, 2024
Drug: Pembrolizumab/Vibostolimab; Carboplatin and 5 more · For: Metastatic Non-Small Cell Lung Cancer
Sites: Colorado Springs, Colorado; Fort Collins, Colorado; Jacksonville, Florida · 149 sites in all
- MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05007106 · 611 participants · Start Sep 16, 2021 · Primary completion Aug 5, 2025
Drug: Pembrolizumab/Vibostolimab Co-Formulation; Pembrolizumab and 10 more · For: Uterine Cervical Neoplasms; Endometrial Neoplasms; Squamous Cell Carcinoma of Head and Neck and 8 more
Sites: Anchorage, Alaska; Duarte, California; Orange, California · 73 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05298423 · 610 participants · Start May 3, 2022 · Primary completion Jun 15, 2026
Drug: pembrolizumab/vibostolimab; durvalumab and 5 more · For: Carcinoma, Non-Small-Cell Lung
Sites: Long Beach, California; Los Angeles, California; Hollywood, Florida · 160 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT02720068 · 481 participants · Start May 2, 2016 · Primary completion Mar 15, 2024
Drug: Favezelimab; Pembrolizumab and 6 more · For: Neoplasms
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT02964013 · 474 participants · Start Dec 13, 2016 · Primary completion Jul 24, 2024
Drug: vibostolimab; pembrolizumab and 5 more · For: Neoplasms
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT03564691 · 470 participants · Start Jul 11, 2018 · Primary completion Sep 26, 2025
Drug: MK-4830; Pembrolizumab and 6 more · For: Neoplasms
Sites: San Francisco, California; Detroit, Michigan; St Louis, Missouri · 37 sites in all
- Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05224141 · 460 participants · Start Mar 24, 2022 · Primary completion Jun 4, 2024
Drug: Pembrolizumab/Vibostolimab Co-Formulation; Saline placebo and 4 more · For: Small Cell Lung Carcinoma
Sites: Mobile, Alabama; Los Angeles, California; Boca Raton, Florida · 140 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Small Cell Lung Carcinoma
- R-DXdDS 6000a, MK-5909Phase 310 trials
Merck & Co. · Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
- ObrixtamigBI 764532Phase 36 trials
Boehringer Ingelheim · Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology
- AL8326Phase 34 trials
Advenchen Pharmaceuticals, LLC. · Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms
- coformulation favezelimabMK-4280APhase 33 trials
Merck & Co. · Small Cell Lung Carcinoma, Solid Tumors, Hematologic Malignancies
- MK-4830Phase 210 trials
Merck & Co. · Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Esophageal Squamous Cell Carcinoma
- CBX-12Phase 21 trial
Cybrexa Therapeutics · Solid Tumor, Adult, Epithelial Ovarian Cancer, Small Cell Lung Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Merck & Co..
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.